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Brain regions contain diverse populations of neurons that project to different long-range
targets. The study of these subpopulations in circuit function and behavior requires a
toolkit to characterize and manipulate their activity in vivo. We have developed a novel
set of reagents based on Pseudorabies Virus (PRV) for efficient and long-term genetic
tagging of neurons based on their projection targets. By deleting IE180, the master
transcriptional regulator in the PRV genome, we have produced a mutant virus capable
of infection and transgene expression in neurons but unable to replicate in or spread
from those neurons. IE180-null mutants showed no cytotoxicity, and infected neurons
exhibited normal physiological function more than 45 days after infection, indicating
the utility of these engineered viruses for chronic experiments. To enable rapid and
convenient construction of novel IE180-null recombinants, we engineered a bacterial
artificial chromosome (BAC) shuttle-vector system for moving new constructs into the
PRV IE180-null genome. Using this system we generated an IE180-null recombinant virus
expressing the site-specific recombinase Cre. This Cre-expressing virus (PRV-hSyn-Cre)
efficiently and robustly infects neurons in vivo and activates transgene expression from
Cre-dependent vectors in local and retrograde projecting populations of neurons in the
mouse. We also generated an assortment of recombinant viruses expressing fluorescent
proteins (mCherry, EGFP, ECFP). These viruses exhibit long-term labeling of neurons in
vitro but transient labeling in vivo. Together these novel IE180-null PRV reagents expand
the toolkit for targeted gene expression in the brain, facilitating functional dissection of
neuronal circuits in vivo.
Keywords: pseudorabies virus, retrograde tracing, viral tracing, immediate early gene (IEG), auditory cortex, non-
toxic retrograde labeling, secondary visual cortex
INTRODUCTION
Neuroinvasive viruses have become an essential part of the sys-
tems neuroscience toolkit as a vehicle for delivery of genetic
material into neurons. Their applications range from anatomical
tracing with fluorescent proteins to monitoring and manipulating
the activity of defined populations of cells (Boyden et al., 2005;
Deisseroth, 2011; Sasaki et al., 2011; Akerboom et al., 2012).
Viral approaches can be used to deliver transgenes into species in
which it is not possible or convenient to produce transgenic ani-
mals. Additionally, targeted viral injections can label anatomically
restricted populations of neurons.
One powerful approach to labeling neuronal subpopula-
tions exploits the ability of certain viruses to infect axon
terminals and undergo retrograde transport to the soma,
thereby labeling neurons that project to the injection site.
This approach can target populations of projection neurons
without the need for a cell-type specific promoter to direct
gene expression. However, the utility of existing viral systems
for retrograde labeling is limited by a number of restric-
tions, including infection inefficiency, unpredictable tropism,
cytotoxicity, limited payload capacity, safety concerns and/or
unavailability. Our goal was to produce a set of retro-
grade viral tools that would be suitable not only for the
mapping of connectivity, but for the long-term manipula-
tion of specific anatomically and genetically defined neuronal
populations.
PRV is a large double stranded DNA virus in the alphaher-
pesvirinae subfamily of herpesviridae. Because PRV efficiently
labels local and retrograde populations and is transmitted tran-
synaptically, it has been used widely for polysynaptic circuit
tracing (Strack and Loewy, 1990; Kim et al., 1999; Yang et al.,
1999; Aston-Jones and Card, 2000; Smith et al., 2000; Card and
Enquist, 2001; Horváth et al., 2002; Yoon et al., 2005; Willhite
et al., 2006; Campbell and Herbison, 2007; Boldogkoi et al., 2009;
Braz et al., 2009; Ohara et al., 2009a,b). However infection with
PRV is cytotoxic, killing cells in days or even hours depending
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on the strain and titer of infection and is eventually lethal to
the animal. To restrict PRV labeling to first order neurons and
eliminate its toxicity, we took advantage of the fact that PRV
has only one immediate early gene, IE180, which acts as the
master switch of the PRV transcriptional cascade (Ihara and Ben-
Porat, 1985). By deleting IE180, we blocked the viral replication
cycle, thereby eliminating PRV cytotoxicity, viral particle pro-
duction, and transsynaptic spread. Here we show that IE180-
null mutants grown in an IE180 expressing cell line are capable
of infecting neurons and undergo retrograde transport in the
central nervous system. One mutant, PRV-hSyn-CRE, is capable
of efficiently labeling even sparse subpopulations of neurons
projecting to the site of injection in a reporter mouse. Fur-
thermore, IE180-null PRV-infected neurons persist for months
after injection and are physiologically indistinguishable from
uninfected cells. Unlike other retrograde viruses such as rabies
virus (RV) and herpes simplex virus 1 (HSV-1), PRV is not a
human pathogen and is safer and more convenient to work with
(Kluge et al., 1999; Pomeranz et al., 2005). The IE180-null PRV
system described here represents a novel set of reagents useful for
both anatomical and functional retrograde circuit mapping and
analysis.
METHODS
The PRV Becker bacterial artificial chromosome (BAC) vector
(pBecker3) described previously (Smith and Enquist, 2000)
was modified using a λ-mediated counter selection BAC
recombination system from Gene Bridges (Gene Bridges
#K002) (Muyrers et al., 1999). We first synthesized a plasmid
containing two FRT sites flanking a multiple cloning site
(IDT Inc.). An rpsL-zeo positive/negative selection cassette
was then subcloned into the multiple cloning site (MCS)
yielding the vector PZ26 (FRT-Neo-rpsL-FRT). PZ26 was
amplified with primers containing homology to IE180
(CGGCCCGCCAGAGAAGAGTCTTCTTCTTCTCCTCCTCCG-
GCCGCCTTCCTCCTTCTTCTCGGAATTCGCCCTTAACCATA
TG and CAAACTCTTTTCTCACCCGATGGGAGAAGGAGGA
GAAGGGGACCGGGGGACCGCGGGAGGGCCAGTGTGGATG
GATATCTGGCAG). There are two copies of the PRV IE180 gene,
one copy in each of the large inverted repeats surrounding the
unique short region of the genome. After replacing the first copy
of IE180 with the FRT-rpsL-Zeo-FRT cassette, we transformed
the BAC clone with 707-FLPe (Gene Bridges) and induced the
expression of Flp recombinase to excise the cassette leaving
behind one FRT site. BACs that successfully excised the cassette
were selected on streptomycin and verified by diagnostic digest.
These steps were repeated to remove the second copy of IE180
yielding a PRV viral BAC with FRT sites replacing both copies of
IE180 (PZ42).
To make an IE180- and Us9- null pBecker (PZ57) BAC, we
used recombineering to replace Us9 in PZ42 with a neo-rpsL
cassette (Gene Bridges) amplified with Us9 homology arms
(primers GGAGAACCGGCCCGCCCGCATTCCGACATGCC-
CGCCGCCGCCCCCGCCGACATGGACACGGGCCTGGTGAT
GATGGCGGGATCG and GCGGCGGGGCGGGCGGCCACC
ACCCGCTCGCTACACGTGCCGGGCGATGATGCCCCCGATT
CAGAAGAACTCGTCAAGAAGGCG). Positive clones were
selected on kanamycin plates and verified by diagnostic
digest. The shuttle vector was constructed by subcloning the
em7 (promoter)-zeocin cassette into a minigene containing a
multiple cloning site flanked by homology arms matching the
rpsL sequence, which was synthesized by IDT [HA–MCS–HA
(GGCCTGGTGATGATGGCGGGATCGTTGTATATTTC TTGA-
CACCTTTTCGGCATCGCCCTAAAATTCGGCGTCCTCATATT
GTGTGAGGACGTTTTATTAC—AACGTTACGCGTAAGCTTC
TAGAATTCATTAATGCATGC–GGCGGCGAATGGGCTGACCG
CTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAG
CGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGA)].
Transgenes were subcloned into the MCS of the shuttle vector
and the recombination cassette was amplified using the shuttle
forward (GGCCTGGTGATGATGGCGGGATCGTTG) and shut-
tle reverse (TCAGAAGAACTCGTCAAGAAGGCGATAGAAG)
primers. Transgenes constructs cloned into this BAC include
the synapsin promoter expressing Cre (hSyn-Cre), and the
elongation factor 1a (EF1a) promoter driving expression of
Green Fluorescent Protein, mCherry or Cyan fluorescence
protein (EF1a-EGFP, EF1a-mCherry and EF1a-ECFP).
INDUCIBLE IE180 EXPRESSION CELL LINE
As previous work had indicated that constitutive expression of
IE180 is toxic to cells (Taharaguchi et al., 2003), we constructed
the cell line PK15-IE180, which has conditional IE180 expres-
sion. We made a cell line with the reverse tetracycline-controlled
transactivator (rtTA) and then inserted a transgene under the
control of the tetracycling-inducible promoter, pTRE (promoter
tetracycline response element) (Gossen et al., 1995). We inserted
the rtTA sequence into PK15 cells by infecting with the rtTA-
hygro Murine Stem Cell Virus (MSCV) retrovirus and selecting
for transduced cells with hygromycin, yielding the cell line PK15-
rtTA. We next used BAC recombineering to subclone IE180 from
pBecker3 into the pUC19 cloning vector (Smith and Enquist,
2000). IE180 was then excised from this vector and subcloned
into the retroviral vector under the control of the rtTA-regulated
pTRE promoter pTREtight (TTiGP). PK15-rtTA cells were then
infected with TTiGP-IE180 retrovirus and plated at clonal density
in the presence of puromycin to select positive clones. Individual
clones were then tested by transfection of PZ42 IE180-null BAC in
the presence of 2 µg/ml doxycycline. The clone that produced the
highest titers was selected, expanded, and used for making stocks
of IE180-null mutants.
VIRUS PRODUCTION
The initial production of viruses from PRV BACs is accomplished
by transfection of BAC DNA prepared from 1 ml of an overnight
culture into a 35 mm dish of PK15-IE180 cells by Lipofectamine
2000 (Life Technologies). Immediately after transfection 2 µg/ml
doxycycline was added to the media. When ∼80% of cells exhib-
ited cytopathic effects (typically 2–4 days after transfection) the
virus stock was harvested, and used to infect a larger volume of
cells. Subsequently, new batches of viral stocks were prepared by
amplifying them in PK15-IE180 cells. Virions were concentrated
and titered as previously described (Card and Enquist, 2001) on
PK15-IE180 cells in the presence of 2 µg/ml doxycycline in the
culture media.
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DISSOCIATED NEURONAL CULTURE
Mouse cortical and hippocampal tissue was acquired from Brain-
Bits (BrainBits® LLC, Springfield, IL). The tissue was dissociated
and plated at approximately 16,000 cells/cm2 in poly-D-lysine
coated tissue culture plates (BrainBits standard protocol1). Dur-
ing plating in NbActiv1 media, neurons were infected with PRV
HKO128 at a multiplicity of infection (MOI) of 10 and incubated
at 37◦C. Six hours after plating 100% of the media was replaced.
Thereafter, 50% of the media was exchanged for new NbActiv1
media every 3 days.
ANIMAL CARE AND VIRAL INJECTIONS
All animal protocols were approved by the Cold Spring Harbor
Laboratory Animal Care and Use Committee and carried out in
accordance with National Institutes of Health standards. Mice
were anesthetized with a mixture of ketamine/medetomidine
(120 mg/kg ketamine, 0.5 mg/kg medetomidine). For each injec-
tion a small craniotomy was made above the injection site and
a glass micropipette was used to deliver ∼250 nl of the virus.
Injections were performed in mice of either sex by delivering
brief pulses of pressure at 0.2 Hz using a Picospritzer II (Parker),
each pulse delivering ∼2 nl. Ai14 mice (LSL-tdTomato, JAX labs)
were injected with PRV-hSyn-CRE IE180-null PRV (titer 3.0 ×
109 pfu) in left auditory cortex (2.5 mm posterior to bregma,
4.5 mm lateral from midline) with a single injection at a depth
of 500 µm from the pia. ∼250 nl of PRV EF1a-EGFP, PRV-
EF1a-Mcherry and PRV-EF1a-ECFP were injected at titers of
∼7× 108 pfu.
HISTOLOGY AND CONFOCAL IMAGING
Mice were deeply anesthetized with ketamine/medetomidine
and transcardially perfused with 0.15 M NaCl followed by 4%
paraformaldehyde (PFA). The brains were removed and post-
fixed overnight in 4% PFA before being sectioned into 100 µm
slices. Slices were mounted in VectaShield with DAPI (Vector
Laboratories) and imaged using the LSM710 confocal microscope
(Zeiss). Z-stacks spanning 50 µm were acquired of the entire
brain slices or regions of interest. For presentation of the distri-
bution of labeled neurons, maximum intensity projection images
were calculated using ImageJ (NIH) software.
SLICE PREPARATION AND ELECTROPHYSIOLOGY
Ai14 mice were injected with PRV-hSyn-Cre in the left auditory
cortex at postnatal day 30. At 40–70 days post-injection, animals
were anesthetized with isofluorane and perfused intracardially
with cold artificial cerebrospinal fluid (ACSF) containing 127 mM
NaCl, 25 mM NaHCO3, 25 mM D-glucose, 2.5 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, and 1.25 mM NaH2PO4, aerated with 95%
O2 5% CO2. The brains were transferred to a chilled slicing solu-
tion composed of 110 mM choline chloride, 25 mM NaHCO3,
25 mM D-glucose, 11.6 mM sodium ascorbate, 7 mM MgCl2, 3.1
mM sodium pyruvate, 2.5 mM KCl, 1.25 mM NaH2PO4, and 0.5
mM CaCl2. We made 300 µm thick horizontal slices that were
incubated in ACSF at 34◦ for 20–30 min and then kept at room
temperature during the experiments.
1http://goo.gl/dRqh2d
To examine the physiological properties of retrogradely labeled
neurons in the right auditory cortex, we made current-clamp
recordings of excitatory neurons in layers 3 and 5 45–80 µm
below the surface of the slice. Neurons were patched with elec-
trodes (4–6 M) containing intracellular solution (128 mM K-
methylsulfate, 4 mM MgCl2, 10 mM HEPES, 1 mM EGTA, 4
mM Na2ATP, 0.4 mM Na2GTP, 10 mM Na-phosphocreatine, and
0.015 mM Alexa-594 (Molecular Probes, Eugene, Oregon, USA),
pH 7.25, 300 mOsm). The membrane resting potential and input
resistances reported were all measured in whole-cell configuration
immediately after break-in. Cells were included in analysis if their
resting membrane potential did not become depolarized during
the recording, and series resistance did not increase above 35 M.
Statistical comparisons were done using Wilcoxon sign-rank test
comparing pairs of nearby PRV-infected and control neurons.
IN VIVO PHYSIOLOGY
Two FVB mice were injected with AAV-EF1a-DIO-hChR2
(H134R)-EYFP supplied from UNC vector core. 2–4 weeks
after injection, the mice were anesthetized using a mixture
of ketamine/medetomidine (120 mg/kg ketamine, 0.5 mg/kg
medetomidine) and placed in an orbitonasal stereotaxic appara-
tus. A cranial window∼2 mm in diameter was made to expose the
left primary auditory cortex and the dura was resected. For light
stimulation, 1 ms pulses of blue light at 10 mW from a 473 nm
laser were projected on the cortical surface. Spike responses were
recorded extracellularly using acute NeuroNexus probes. Signals
were amplified, filtered 600–9000 Hz and acquired using the
Cheetah 32 data acquisition system (Neuralynx). Single units were
identified after spike sorting using MClust software.
RESULTS
PRODUCTION AND VALIDATION OF IE180-NULL PRV
Herpes viruses have three phases of gene expression: immediate
early (IE), early (E) and late (L). IE gene expression occurs in
the absence of new protein synthesis and is activated by viral
transactivators that enter the cell in the viral tegument, a pro-
teinaceous layer between the capsid and envelope. IE genes are
required for E gene expression, whose gene products promote the
replication of viral DNA. Newly replicated DNA is the substrate
for L gene expression. Herpes Simplex Virus-1 (HSV-1) encodes
five immediate early genes, and the recombinant HSV-1 used for
retrograde tagging has deletions in two of the essential IE genes;
ICP4 and ICP27, and also carries a mutation in the tegument
protein VP16 that blocks transactivation of the other 3 IE genes
(Lilley et al., 2001). The single PRV IE gene, IE180, acts as
the master transcriptional regulator of PRV gene expression. We
reasoned that elimination of the IE180 gene should completely
prevent PRV replication and spread.
The PRV genome is∼143 kb and consists of two long inverted
repeat regions flanking a shorter unique region. The gene encod-
ing IE180 is present in duplicate; one in each of the inverted repeat
regions. We used BAC recombineering methods to delete both
copies of the IE180 open reading frame (ORF) from pBecker3,
a self-excising PRV BAC carrying the PRV genome (Smith and
Enquist, 2000; Figure 1A). Transfection of this BAC into PK15
cells produced no infectious viral particles detectable by plaque
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FIGURE 1 | Design and construction of the IE180-null PRV mutant.
(A) Recombineering strategy for deletion of both copies of IE180 from
the PRV pBecker3 BAC carrying the PRV genome. (B) Inducible IE180
trans-complementation system for packaging IE180-null PRV. To make
the PK15-IE180 cell line we first stably expressed the reverse
Tet-transactivator rtTA in PK15 cells. We then inserted IE180 under the
control of the Tet regulated pTreTIGt promoter. The addition of
doxycycline to the cell growth media results in IE180 expression and
thus viral production. (C) PK15-rtTA cells and PK15-IE180 cells were
infected with IE180-null PRV and imaged 48 h later. Cytopathic effects
associated with PRV replication were observed only in PK15-IE180 cells
and were enhanced by the addition of doxycycline. (D) Titers of viral
supernatants produced by PK15 and PK15-IE180 cells infected with
IE180-null PRV (harvested 3 days after infection) at MOI of 1, 0.1 or
0.01 quantified on PK15-IE180 cells. No infectious material can be
detected in supernatants of PK15 cultures lacking IE180.
assay, showing that deletion of IE180 was sufficient to abolish viral
replication and packaging.
To enable construction and propagation of IE180-null
mutants, we developed a method to express IE180 in trans. Co-
transfection of the IE180–null BAC with an IE180 expression plas-
mid into PK15 cells resulted in recombination events between the
plasmid and BAC that produced replication competent, IE180-
expressing virus. We therefore constructed a cell line that carried
a genomic cassette for conditional expression of IE180, since this
genomic IE180 would be less likely to undergo recombination.
The cell line was derived from PK15 cells that efficiently replicate
PRV. Because previous work suggested that constitutive expres-
sion of IE180 is toxic (Taharaguchi et al., 2003), we placed IE180
under the control of a tetracycline inducible promoter (PK15-
IE180 cells, Figure 1B; Gossen et al., 1995).
To validate the replication deficient phenotype of the IE180
deleted PRV BAC and the complementation efficiency of the
PK15-IE180 cell line, we first transfected IE180-null viral BAC
DNA into PK15-rtTA or PK15-IE180 cells in the presence
or absence of doxycycline (Figure 1C). Cytotoxic effects were
observed only in transfected PK15-IE180 cells and infectious
virions were produced only from this cell line. These experi-
ments demonstrated the requirement of IE180 expression for the
production of infectious virus from the IE180-null PRV BAC
(Figure 1C). Since BAC transfections are often inefficient and
variable, we next tested the requirement of IE180 for viral prop-
agation during serial viral passaging. We harvested the virions
produced by transfection of the IE180-null BAC into PK15-IE180
cells and used this stock to infect PK15 or PK15-IE180 cells in the
presence or absence of doxycycline. We collected the supernatants
from each culture and titered infectious material by plaque
assay on PK15-IE180 cells. No plaques were produced from the
supernatants harvested from PK15 cells (detection threshold of
103 pfu/ml) (Figure 1D). On the other hand, while some pfus
were generated from the supernatants of PK15-IE180 cells in
the absence of doxycycline, the addition of doxycycline increased
the resulting viral titers 105–106 fold (Figure 1D). Infectious
virus produced from the PK15-E180 cell line in the absence
of doxycycline likely reflects low level leak expression of IE180
from the TTiGP promoter. However, such expression does not
appear to be cytotoxic and does not interfere with the propagation
of PK15-IE180 cells which retain the ability to produce high
titer PRV stocks after as many as 20 passages. After the initial
transfection, IE180-null mutants can be propagated and amplified
in PK15-IE180 cells and concentrated to produce titers exceeding
109 pfu/ml. Together these results indicate that deletion of IE180
from the genome of PRV blocks production of infectious virus
particles and that high titer stocks of IE180-null PRV mutants can
be produced when IE180 is complemented in trans.
INSERTION OF TRANSGENES INTO IE180-NULL PRV MUTANTS
To streamline the construction of recombinant PRV in the IE180-
null background, we developed a shuttle system for reliable inser-
tion of transgenes into the IE180-null PRV BAC. We first inserted
a recombineering landing pad, carrying an rspL-kanR/neoR selec-
tion cassette that confers resistance to kanamycin and sensitivity
to streptomycin into the IE180-null PRV genome disrupting the
Us9 locus. Us9 is required for anterograde viral spread in vivo
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(i.e., spread from presynaptic to postsynaptic neurons) but its
deletion has no effect on primary infection properties of PRV
(Lyman et al., 2007). We then constructed a shuttle vector with
a Zeocin resistance cassette and a MCS flanked by homology to
the landing pad (Figure 2A). The sequence flanking the selection
cassette is specific to the landing pad inserted into Us9 and
lacks homology to any other region in the viral genome, which
improves specificity of recombination. Transgenes can be inserted
readily into the MCS using standard cloning techniques. The
shuttle cassette can then be isolated by PCR amplification or
restriction digestion and used to deliver the transgene into the
PRV IE180-null BAC by recombineering. Successfully modified
BAC clones can then be identified as zeocin- and streptomycin-
resistant and neomycin-sensitive.
To test expression of transgenes in the PRV IE180-null back-
ground, we used the shuttle system to produce several recombi-
nants carrying transgenes encoding different fluorescent proteins.
We used the constitutive Ef1a promoter to drive expression of
EGFP (PRV HKO128), mCherry (PRV HKO242) and ECFP (PRV
HKO243).
These viruses efficiently drove fluorescent protein expression
in PK15 cells (Figures 2B–D) and dissociated neuronal cultures
(Figure 2E). Surprisingly, in vivo injection of PRV HKO128
(expressing EGFP) into auditory cortex labeled only neurons
near the injection site but did not label input structures such as
the contralateral auditory cortex or the medial geniculate body
(MGB) (not shown). Injection into other structures, including
auditory striatium and cerebellum, also failed to label input
structures. Thus in their current form, these reagents are useful
only for in vitro experiments (see Section Discussion).
GENE EXPRESSION FROM IE180-NULL PRV MUTANTS IN VIVO
We hypothesized that the in vivo expression of fluorescent pro-
teins from the recombinants we had generated was either too
weak or too transient to be useful in vivo. However, because even
weak and transient expression of Cre recombinase can effectively
activate gene expression, we expected that an IE180-null PRV
expressing Cre recombinase would be a useful reagent.
To produce a PRV IE180-null recombinant that could be used
in combination with Cre-dependent viruses and Cre-reporter
mice that are already a widely used component of the systems
neuroscience toolkit, we inserted the Cre-recombinase gene under
control of the neuron specific synapsin-1 promoter (hSyn)(Kügler
et al., 2003).
To characterize the ability of IE180-null PRV-hSyn-Cre virus
for retrograde infection after injection in the brain, we injected it
into Ai14 mice, which carry a Cre-dependent tdTomato expres-
sion cassette inserted at the ROSA26 locus (Madisen et al., 2010;
Figure 3A). The distribution of tdTomato fluorescence 4 months
after injection into auditory cortex is shown in Figure 3. In addi-
tion to the site of injection (Figures 3B,C), fluorescent neurons
were found in known input structures of the auditory cortex,
FIGURE 2 | Shuttle vector and landing pad system for streamlining
IE180-null PRV mutant recombinants. (A) A landing pad was inserted
into the PRV IE180-null BAC. The transgene is inserted into a shuttle
plasmid containing homology arms (h.a.) to the landing pad. The
transgene is then amplified together with the Zeocin selection cassette
using standardized primers and inserted into the IE180-null BAC using
recombineering. (B–D) PK15 cells infected with PRV strains expressing
EGFP (PRV HKO128), mCherry (PRV HKO242) and ECFP (PRV HKO243).
(E) Dissociated neurons infected with PRV HKO128, at 3 weeks post
infection.
Frontiers in Neuroanatomy www.frontiersin.org September 2014 | Volume 8 | Article 86 | 5
Oyibo et al. IE180 deleted PRV
FIGURE 3 | Retrograde labeling by PRV IE180-null-hSyn-Cre in primary
auditory cortex. (A) PRV-hSyn-Cre activates tdTomato expression in Ai14
reporter mice. (B) Fluorescence image showing the distribution of tdTomato
labeling in an Ai14 mouse injected with PRV-hSyn-Cre in the primary auditory
cortex. Arrow points to site of injection. (B–G,I,K) Retrograde labeling by
PRV-hSyn-Cre in (C) the auditory cortex ipsilateral to the site of injection,
(D) contralateral auditory cortex, (E) medial geniculate body, (F) ipsilateral
parietal cortex, (G) contralateral parietal cortex, (I) the lateral posterior and the
posterior nuclei in the thalamus and (K) motor cortex. (H) Axonal labeling in
the primary auditory cortex of a mouse injected with AAV-EGFP in the
contralateral parietal cortex, adapted from Allen Mouse Brain Connectivity
Atlas. (J) Axonal labeling in the primary auditory cortex of a mouse injected
with AAV-EGFP in the ipsilateral posterior and lateral posterior nuclei. Scale
bars—300 um.
including the contralateral auditory cortex (Figures 3B,D; Roger
and Arnault, 1989; Oviedo et al., 2010), MGB in the thalamus
(Figure 3E; Roger and Arnault, 1989; Pandya, 1995; Lima et al.,
2009), the ipsilateral posterior parietal cortex (Figure 3F; Reep
et al., 1994; Pandya, 1995) as well as the ipsilateral motor cortex
(Figure 3K; Nelson et al., 2013). Labeled neurons in contralateral
auditory cortex were found primarily in layers 3–5, the established
origin of the callossal projection in the mouse auditory cortex
(Oviedo et al., 2010).
We also observed sparse tdTomato labeling in regions, for
which projections to the auditory cortex have not been previously
described, including the contralateral posterior parietal cortex
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(Figure 3G), the contralateral motor cortex (M1, M2, Figure 3K)
and the posterior and the lateral posterior nuclei in the thalamus
(Figure 3I; Roger and Arnault, 1989; Nelson et al., 2013). To
validate the existence of these projections, we examined antero-
grade labeling data from these areas (collected as a part of the
Allen Mouse Brain Connectivity Atlas) to test for projections to
the primary auditory cortex. We found sparse axonal labeling in
the primary auditory cortex in mice injected with AAV-EGFP in
contralateral posterior parietal cortex (Figure 3H,2 (Allen Insti-
tute for Brain Science, 2013a) as well as the ipsilateral posterior
thalamic nucleus (Figure 3J; Allen Institute for Brain Science,
2013b), confirming the existence of direct inputs from these
areas into auditory cortex. Retrogradely labeled neurons were
also found in zona incerta and nucleus basalis, regions known to
project widely in the neocortex (Mitrofanis, 2005), as well as in the
ventral division of the basolateral amygdala (not shown). These
observations illustrate the broad tropism IE180-null PRV and its
ability to robustly label even exceedingly sparse projections.
The distribution of tdTomato labeling 15 days after injection of
PRV-hSyn-Cre into the secondary visual cortex area AL of an Ai14
mouse is shown in Figure 4. This injection resulted in labeling
of cells at the site of injection (Figure 4A) as well as regions
known to project to area AL, including primary visual cortex
(Figure 4B), primary and secondary auditory cortex, contralat-
eral visual cortex (Figure 4A), anterior cingulate and secondary
motor cortex (Figure 4C), the ipsilateral LP (Figure 4D), VA/VL
and posterior nuclei in the thalamus, the ipsilateral (Figure 4E)
and contralateral amygdala, and the ipsilateral and contralateral
perirhinal cortex (Figures 4F,G).
VIABILITY AND INTRINSIC PROPERTIES OF INFECTED NEURONS
The application of PRV in the study of neural circuits has been
limited by its rapid cytotoxicity; wild-type PRV alters neuronal
properties within hours of infection and cell death follows shortly
thereafter (McCarthy et al., 2009). Since IE180 acts as the master
transcriptional regulator of PRV gene expression, its deletion
should not only prevent replication, production of viral particles,
and spread of infection, but should also eliminate the resultant
cytotoxic effects. We found that Ai14 mice injected with PRV-
hSyn-Cre showed no overt signs of infection even after 6 months
of infection (n = 3 mice). Moreover, tdTomato expressing neurons
were observed at the earliest tested time point of 3 days after
infection (n = 3 mice) and persisted as long as 6 months (the
longest time point examined, n = 3 mice).
To determine the physiological health of cells infected with
PRV-hSyn-Cre we performed slice recordings of retrogradely-
infected neurons in the auditory cortex contralateral to the site
of infection in Ai14 mice. We measured the resting potential,
input resistance and f/I (firing rate/current) curves of neurons
40–70 days after infection (mean = 48.75 days, ±14.2). We found
that the intrinsic properties of IE180-null PRV infected cells
(n = 9 pairs in 4 animals) were indistinguishable from adjacent
uninfected control cells (Figures 5A–D, mean distance between
pairs = 37.1± 31.9 µm.
2http://goo.gl/J4F4z0
FIGURE 4 | Retrograde labeling by PRV IE180-null-hSyn-Cre in
secondary visual cortex. (A) Fluorescence image showing the distribution
of tdTomato labeling in an Ai14 mouse injected with PRV-hSyn-Cre in the
secondary visual cortex. Arrow points to site of injection. (B–G) Retrograde
labeling by PRV-hSyn-Cre in (B) primary visual cortex ipsilateral to the site of
injection, (C) anterior cingulate cortex, (D) lateral posterior nucleus of the
thalamus, (E) ipsilateral amygdala, (F) contralateral perirhinal cortex, (G)
ipsilateral perirhinal cortex. Scale bars—300 um.
PINPing WITH PRV
One possible application of IE180-null PRV mutants is the expres-
sion of ligand or light-gated ion channels in neurons based on
the target of their projections. This would allow application of the
Photostimulation-assisted Identification of Neuronal Populations
(PINP) technique (Lima et al., 2009), wherein populations of
neurons defined by their projection pattern are identified during
electrophysiological recordings. To explore the potential of IE180-
null PRV-hSyn-Cre in such experiments, we tested its ability to
induce ChR2 expression from an adeno-associated virus (AAV)
carrying a Cre-dependent FLEX-ChR2-YFP expression cassette
(n = 2 mice). When AAV FLEX-ChR2-YFP was injected into
the left auditory cortex and PRV-hSyn-Cre in the right auditory
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FIGURE 5 | Intrinsic properties of PRV IE180-null hSyn-Cre infected
neurons are indistinguishable from control cells 40–70 days after
infection. (A) tdTomato fluorescence in neurons retrogradely labeled with
PRV IE180-null hSyn-CRE in an acute slice of Auditory cortex before
recording. Scale bar ∼200 um. (B) Resting potential is unaffected in PRV
infected neurons (p = 0.7266). (C) Input resistance is unaffected in PRV
infected neurons (p = 0.8750). (D) F/I (firing rate/current) curves are
unchanged by PRV infection (p = 0.7153). (E) Strategy for ChR2-tagging of
callosal projection neuron in Auditory cortex using PRV-hSyn-Cre. (F) Raster
of light-evoked responses of a presumed callosal projection neuron. Blue
bar- light stimulus. Inset shows extracellular spike waveforms of this
neuron, bar—200 us. (G) ChR2-YFP expression in PRV-tagged callosal
projection neurons in the auditory cortex. AAV-EF1a-DIO-hChR2
(H134R)-EYFP was injected into the left auditory cortex and IE180-null
PRV-hSyn-Cre was injected into the right auditory cortex, shown here is the
left auditory cortex with callosal projection neurons labeled as a result of
dual infection. Scale bar—300 um.
cortex (Figure 5E), ChR2-YFP fluorescence was confined to layers
3–5 of the left auditory cortex (Figure 5G), the origin of the
contralateral projection in mouse auditory cortex (Oviedo et al.,
2010). Neurons, which responded to brief flashes of blue light,
could be identified during in vivo extracellular recordings from
injected mice (Figure 5F). Together, these results illustrate the
utility of IE180-null PRV mutants as agents for specific manip-
ulation of neurons based on the targets of their projections.
DISCUSSION
By deleting IE180, the master transcriptional regulator in the
PRV genome, we have produced PRV mutants capable of long-
term labeling of local and retrograde neuronal populations.
We have engineered a rapid and convenient system for the
construction of novel IE180-null PRV recombinants. Using this
system we made an assortment of recombinant viruses expressing
the fluorescent proteins mCherry, EGFP, and ECFP as well as
the site-specific recombinase Cre. The Cre-expressing virus, PRV-
hSyn-Cre is a versatile tool capable of efficient and robust labeling
of neurons in vivo through the activation of transgene expression
from Cre-dependent constructs in transgenic mice or introduced
via other viral vectors. These IE180-null PRV reagents expand
the toolkit for targeted gene expression in the brain, facilitating
functional dissection of neuronal circuits in vivo. Several viral
vectors, including RV, AAVs, lentiviruses and canine adenovirus,
have been used as vehicles for retrograde transgene expression.
However, many of these reagents are limited by pathway tropisms,
efficiency of retrograde transport or cytotoxicity. RV is widely
used for its ability to spread transynaptically between neurons,
enabling its use as a multisynaptic or monosynaptic tracer, but
its applications are limited by its cytotoxicity (Ugolini, 1995;
Wickersham et al., 2007; Ohara et al., 2009a). Recombinant
AAV, which are the most widely used viral vectors for delivering
transgenes into the brain, show some capacity for retrograde
spread (Burger et al., 2004; Kaspar et al., 2004). However, their
retrograde transport is often inefficient (but see Aronoff et al.,
2010; Nelson et al., 2013) and limited to specific projection
pathways. For example, AAV5 undergoes retrograde transport
to the entorhinal cortex after injection into the dentate gyrus
but fails to label extensive callosal inputs to the auditory cortex
(Aschauer et al., 2013). Lentiviral vectors can be pseudotyped
with the glycoproteins of different viruses to enable retrograde
infection (Carpentier et al., 2011; Kato et al., 2011; Hirano et al.,
2013), but these are often inefficient, yield poor expression,
and suffer from pathway-specific tropism. Recombinant canine
adenoviruses (CAV-2) have also been manipulated for long-term
retrograde labeling of neuronal populations (Soudais et al., 2004),
but again there is evidence for pathway-specific tropism (Senn
et al., 2014). The tropisms and other limitations of current viral
vectors for non-lethal retrograde labeling highlight the need for a
diverse set of viral tools.
HSV-1 has been used for retrograde targeting of neuronal
populations in long-term electrophysiological and behavioral
experiments (Lilley et al., 2001; Lima et al., 2009; Znamenskiy and
Zador, 2013). Unfortunately, this particular HSV-1 mutant is a
patented and proprietary virus that is no longer available for aca-
demic use. Inspired by this work, we pursued a conceptually sim-
ilar strategy in modifying Pseudorabies virus (PRV). Wild-type
and attenuated strains of PRV are widely used in neuroanatomical
studies for their ability to infect neurons retrogradely and spread
between synaptically connected cells (Kim et al., 1999; Yang et al.,
1999; Brideau et al., 2000; Card and Enquist, 2001, 2012). These
properties make PRV useful as a transsynaptic tracer, labeling
connected populations of neurons throughout the brain within
days of infection. However, infection with wild-type or attenuated
PRV results in physiological abnormalities in the infected neurons
within hours and eventual death of the host, preventing its appli-
cation in behavioral or physiological experiments requiring long-
term cell viability (Aston-Jones and Card, 2000; McCarthy et al.,
2009).
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PRV mutants deficient in transneuronal spread have been con-
structed by eliminating the expression of viral genes encoding gly-
coprotein B (gB) required for virion infection and cell-cell spread,
or thymidine kinase (TK) required for viral DNA synthesis in
terminally differentiated cells (DeFalco et al., 2001; Curanovic
and Enquist, 2009). However, while the deletion of these genes
inhibits viral replication (TK) or spread (gB), neither deletion
fully eliminates expression of native viral genes. Consequently,
TK/gB-null viruses retain cytotoxicity and are not suitable for
experiments that require long term cell survival.
Here we describe the production of a new set of reagents
based on IE180-null PRV mutants, for targeted long-term genetic
tagging of neurons in the brain. By deleting IE180, the singular
master transcriptional regulator of PRV, we eliminated viral repli-
cation and cytotoxicity without affecting the capacity of IE180
complemented PRV particles for retrograde axonal transport.
IE180-null PRV mutants efficiently transduce neurons in vivo,
undergo retrograde transport, and efficiently label neurons for at
least several months after CNS injection. Furthermore, infected
neurons exhibit normal intrinsic physiological properties more
than a month after infection, demonstrating that IE180-null
PRV mutants do not perturb cellular physiology. Together, these
properties make IE180-null PRV mutants suitable for not only
anatomical tracing studies, but also experiments requiring long-
term labeling.
To facilitate the construction of recombinant IE180-null PRV
mutants, we used a shuttle-vector based strategy that avoids many
of the pitfalls of BAC recombineering and reliably yields recombi-
nant IE180-null PRV mutants carrying transgenes of interest with
a turnaround time of∼13 days (4 days to insert the transgene into
the shuttle plasmid and validate, 3 days for BAC recombineering,
DNA preparation and transfection into PK15-IE180 cells and 4–6
days to produce and validate high titer viral neurostocks in vitro).
However, a few weeks are needed for optimization of injection and
validation of labeling in vivo.
Although in vivo expression of Cre recombinase from IE180-
null PRV hSyn-Cre is sufficient to drive recombination in neu-
ronal populations that send even exceedingly sparse projections
to the site of injection, expression of fluorescent proteins was
either too weak or too transient in vivo to drive robust expres-
sion in retrogradely labeled neurons from injections in auditory
cortex. This contrasts with the observed expression of fluorescent
proteins from PRV in cultured neurons more than 30 days after
infection. Although the precise reason for this poor expression in
vivo is unclear, expression levels may be improved in the future by
selection of promoters that perform better in the context of the
PRV genome as has been done with HSV-1 vectors (Neve et al.,
2005).
PRV can be engineered to deliver large transgene cassettes. Up
to ∼30 kbp can be inserted into the closely related HSV genome
without interfering with virus production; a similar capacity is
likely for PRV (Reay et al., 2004). This capacity could be exploited
to deliver large promoter regions to limit transgene expression
to genetically defined cell-types. PRV also holds promise as an
alternative to RV for trans-synaptic labeling of neuronal popu-
lations. Since the replication and virion production capacity of
IE180-null PRV can be rescued by providing IE180 expression
in trans (e.g., in the PK15-IE180 cell line), this strategy could
be applied to enable the transneuronal spread of the virus from
anatomically or genetically defined populations of cells to their
inputs. Like RV lentivirus and AAV, herpesviruses are amendable
to pseudotyping, which may with further development allow for
targeting infection to particular cell types (Anderson et al., 2000;
Zhou and Roizman, 2005). Moreover, because of its packaging
capacity and non-pathogenicity in humans, the use of PRV as
a tool in human gene therapy has long been pursued. Repli-
cation incompetent, IEG null PRV represents a fundamental
advancement towards this goal (Prieto et al., 2002; Boldogköi and
Nógrádi, 2003).
Biosafety level (BSL) classification can be an important deter-
minant in the selection of viral tools to be used for a given
experiment, as implementation of the appropriate safeguards
can be expensive and time consuming. There are no specific
official (CDC, NIH, WHO, USDA) references to how replicating
PRV should be classified. However, it is reasonable that IE180-
null PRV should be classified in the lowest risk group BSL-1.
Unmodified PRV does not infect humans, and thus by defini-
tion is classified as Risk Group 1 (RG1; National Institutes of
Health, 2002; Centers for Disease Control, 2009; World Health
Organization WHO, 2014). Concerns about PRV as a biohazard
derive from the fact that the wild-type replicating virus is an
animal pathogen, although it is not a human pathogen (Pomeranz
et al., 2005; Card and Enquist, 2012). Specifically it causes an
economically important disease of swine (Kluge et al., 1999).
Naturally occurring strains of the virus have the capacity to infect
and kill a broad range of mammalian hosts with the important
exception of higher primates (Nara, 1982). Furthermore, even the
attenuated but replication-competent PRV tracing strains will kill
infected animals. Out of general concern for animals, particularly
swine, some biosafety committees tend to err on the conservative
side by requiring PRV work be treated as BSL-2. The IE180-
null PRV described in this manuscript is completely replication
incompetent: when stocks are prepared on complementing cells,
the virus particles produced are capable of infecting a cell but
not of carrying out replication of viral DNA or production of
virus particles. The infection cannot spread in vitro or in vivo.
Importantly, IE180-null PRV does not kill animals even when
high titer stocks are injected directly into the brain. Therefore,
working with IE180-null PRV presents minimal risks to the
investigator and animals and as such can reasonably be classified
as BSL-1.
In summary, IE180-null PRV recombinants can be constructed
that enable the expression of transgenes to facilitate the labeling
and functional dissection of anatomically defined cell types. The
large genome size of PRV (∼143 kb) can accommodate much
larger expression cassettes than is possible with other commonly
used viral vectors. Unlike its cousin HSV-1, wild-type PRV has
a broad host range from some avian species to a number of
mammals including Rhesus monkeys and marmosets. However,
PRV is not pathogenic in humans, and fewer safety concerns are
associated with its application in the laboratory (Kluge et al.,
1999; Pomeranz et al., 2005). The family of immediate-early gene
deficient PRV vectors described here offers a novel vehicle for gene
delivery in the central nervous system.
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